Sujata Narayanan
Executive Medical Director, Global Development Lead Pfizer
Seminars
Tuesday 4th November 2025
Vedotins & Immunotherapy: Exploring Advances in Bladder Cancer
11:00 am
- Building on the past success of ADC-immunotherapy combination therapies
- Contextualizing Disitamab Vedotin-immunotherapy success in bladder cancer
- Outlining additional clinical DV-IO combination response in bladder cancer
